We are live on ! Find out more

2,874 hedge funds and large institutions have $105B invested in Pfizer in 2024 Q2 according to their latest regulatory filings, with 212 funds opening new positions, 1,183 increasing their positions, 1,240 reducing their positions, and 172 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more first-time investments, than exits

New positions opened: 212 | Existing positions closed: 172

6% more funds holding in top 10

Funds holding in top 10: 3133 (+2)

0% less funds holding

Funds holding: 2,8752,874 (-1)

0% less capital invested

Capital invested by funds: $105B → $105B (-$332M)

5% less repeat investments, than reductions

Existing positions increased: 1,183 | Existing positions reduced: 1,240

1.16% less ownership

Funds ownership: 67.24%66.08% (-1.2%)

40% less call options, than puts

Call options by funds: $2.36B | Put options by funds: $3.9B

Holders
2,874
Holders Change
-1
Holders Change %
-0.03%
% of All Funds
41.5%
Holding in Top 10
33
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+6.45%
% of All Funds
0.48%
New
212
Increased
1,183
Reduced
1,240
Closed
172
Calls
$2.36B
Puts
$3.9B
Net Calls
-$1.54B
Net Calls Change
+$77.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$571M +$217M +7,886,096 +63%
UBS Group
27
UBS Group
Switzerland
$558M +$91.8M +3,334,517 +20%
Millennium Management
28
Millennium Management
New York
$557M +$334M +12,145,685 +156%
N
29
Nuveen
North Carolina
$516M +$24.1M +876,259 +5%
HSBC Holdings
30
HSBC Holdings
United Kingdom
$513M +$24.5M +891,672 +5%
Ameriprise
31
Ameriprise
Minnesota
$511M -$7.9M -287,124 -2%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$497M +$116M +4,214,400 +31%
T. Rowe Price Associates
33
T. Rowe Price Associates
Maryland
$478M -$222M -8,048,018 -32%
Swiss National Bank
34
Swiss National Bank
Switzerland
$468M -$5.26M -191,000 -1%
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$460M -$35.2M -1,279,238 -7%
VanEck Associates
36
VanEck Associates
New York
$451M +$8.01M +290,760 +2%
Diamond Hill Capital Management
37
Diamond Hill Capital Management
Ohio
$445M -$5.79M -210,435 -1%
Barclays
38
Barclays
United Kingdom
$426M -$174M -6,322,497 -29%
Bank of Montreal
39
Bank of Montreal
Ontario, Canada
$426M +$6.17M +224,272 +2%
Federated Hermes
40
Federated Hermes
Pennsylvania
$418M +$12.9M +470,003 +3%
Fidelity Investments
41
Fidelity Investments
Massachusetts
$393M +$39.5M +1,435,790 +11%
Neuberger Berman Group
42
Neuberger Berman Group
New York
$386M -$40.1M -1,454,733 -10%
UE
43
Unisphere Establishment
Liechtenstein
$354M
Sumitomo Mitsui Trust Group
44
Sumitomo Mitsui Trust Group
Japan
$352M -$83.2M -3,022,827 -19%
First Trust Advisors
45
First Trust Advisors
Illinois
$334M -$66M -2,396,215 -17%
LSV Asset Management
46
LSV Asset Management
Illinois
$329M -$16.6M -603,490 -5%
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$324M -$51.3M -1,863,313 -14%
Caisse de Depot et Placement du Quebec (CDPQ)
48
Caisse de Depot et Placement du Quebec (CDPQ)
Quebec, Canada
$304M -$15.9M -579,050 -5%
National Bank of Canada
49
National Bank of Canada
Quebec, Canada
$297M -$66.3M -2,407,601 -19%
Principal Financial Group
50
Principal Financial Group
Iowa
$292M -$18.1M -657,172 -6%

PFE Hedge Fund Activity: Q2 2024 in Review

2,874 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q2 2024, worth a combined $105B — down 0.32% from $105B a quarter earlier.

Buyers outnumbered sellers: 212 funds opened new PFE positions and 172 closed out — a net gain of 40 holders — while 1,183 added to existing stakes and 1,240 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $346M. The largest seller was Capital World Investors, cutting an estimated $675M.

  • 2,874 institutional investors held Pfizer (PFE) as of Q2 2024, down from 2,875 in Q1 2024.
  • Funds reported $105B of Pfizer stock for Q2 2024, down 0.32% quarter-over-quarter.
  • 212 funds opened new Pfizer positions in Q2 2024 and 172 closed out, a net change of +40 holders.
  • The largest Pfizer buyer in Q2 2024 was Goldman Sachs, an estimated $346M added.
  • The largest Pfizer seller in Q2 2024 was Capital World Investors, an estimated $675M sold.

Based on aggregated 13F filings for Q2 2024.